We studied plasma antibody responses of 35 patients about 1 month after SARS-CoV-2
infection. Titers of antibodies binding to the viral nucleocapsid and spike proteins were …

Abstract Background Coronavirus disease 2019 (COVID-19) is a global pandemic with no
licensed vaccine or specific antiviral agents for therapy. Little is known about the longitudinal …

Background To develop an effective vaccine against a novel viral pathogen, it is important to
understand the longitudinal antibody responses against its first infection. Here we performed …

Understanding how antibody responses to SARS-CoV-2 evolve during infection may
provide important insight into therapeutic approaches and vaccination for COVID-19. Here …

Background Studies have found different waning rates of neutralising antibodies compared
with binding antibodies against SARS-CoV-2. The impact of neutralising antibody waning …

Predictive models of immune protection from COVID-19 are urgently needed to identify
correlates of protection to assist in the future deployment of vaccines. To address this, we …

Longitudinal analysis of clinical serology assay performance and neutralising antibody
levels in COVID19 convalescents - PMC Back to Top Skip to main content NIH NLM Logo …

Surrogate neutralization assays for severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) that can be done without biosafety level 3 containment and in multiple species are …

For the clinical application of semi-quantitative anti-SARS-CoV-2 antibody tests, the
analytical performance and titer correlation of the plaque reduction neutralization test …

Background The COVID-19 pandemic caused by SARS-CoV-2 coronavirus threatens global
public health. Currently, neutralizing antibodies (NAbs) versus this virus are expected to …